Immune Modulation Thymic Peptide

Thymosin Alpha-1

Also known as: Thymalfasin · Zadaxin · Ta1 · Tα1

Thymosin Alpha-1 modulates innate and adaptive immunity through multiple mechanisms. It stimulates dendritic cell maturation and antigen presentation, enhances T helper cell (Th1) responses, and promotes cytotoxic T lymphocyte (CTL) activity against virally infected or cancerous cells. It activates natural...

Half-life ~2 hours (subcutaneous)
Mol. weight 3108.34 Da
Typical cycle 6-12 months for chronic hepatitis; 4-8 weeks for immune optimization
Legal (US) Research chemical - not...
No image
Suggested Providers

No vendors listed for this region yet.

No vendors listed for this region yet.

No vendors listed for this region yet.

No vendors listed for this region yet.

Are you a vendor? Apply to list →

What It Is

Thymosin Alpha-1 modulates innate and adaptive immunity through multiple mechanisms. It stimulates dendritic cell maturation and antigen presentation, enhances T helper cell (Th1) responses, and promotes cytotoxic T lymphocyte (CTL) activity against virally infected or cancerous cells. It activates natural killer (NK) cells and increases production of interferon-gamma, IL-2, and IL-12. TA1 binds Toll-like receptor 9 (TLR9) to stimulate innate immune responses. In chronic viral infections (hepatitis B, C, HIV), TA1 reverses T-cell exhaustion and restores immunocompetence. It also increases dendritic cell MHC II expression for improved antigen presentation.

Supplies Needed

Bacteriostatic Water (30 mL)

Reconstitution solvent

1 mL insulin syringes (U-100)

Subcutaneous injection

Alcohol swabs

Sterilization

Storage

Lyophilized (powder)

Store at 2-8C (refrigerator). Do not freeze Zadaxin brand. Research peptide stable at -20C for 2 years.

Reconstituted (liquid)

Refrigerate at 2-8C; use within 24-48 hours (Zadaxin) or within 30 days (bacteriostatic water reconstitution).

⚠ Disclaimer

This information is provided for educational and research purposes only. Not approved for human consumption by the FDA or any regulatory body. Always consult a qualified medical professional.

Dosing Protocols

Dose1.6 mg
FrequencyTwice weekly
Cycle Length4 weeks
RouteSubcutaneous

Timing: Any time; consistent schedule. Standard Zadaxin dose; use for immune support during illness or infection

↓ Apply these values to the reconstitution calculator
Dose1.6 mg
FrequencyTwice weekly
Cycle Length6-12 months for chronic hepatitis; 4-8 weeks for immune optimization
RouteSubcutaneous

Timing: Any time. Established clinical dose from Zadaxin trials; longer courses for chronic viral infections

↓ Apply these values to the reconstitution calculator
Dose3.2 mg
FrequencyTwice weekly
Cycle Length6 months
RouteSubcutaneous

Timing: Any time. Double dose for severe immunocompromise or cancer adjuvant therapy; used in clinical protocols

↓ Apply these values to the reconstitution calculator

Weekly Timeline

Week Expected Effects
Week 1 Early immune activation; possible mild flu-like response as T-cells are mobilized
Week 2 Improved NK cell activity; enhanced antigen presentation; reduced fatigue
Week 4 Measurable improvement in immune markers; improved response to pathogens
Week 12 Significant immune reconstitution in immunocompromised individuals; improved viral clearance

Reconstitution Calculator

Concentration
Draw to (units)
Draw to (mL)

1 unit on U-100 syringe = 0.01 mL  ·  Always label your vial after reconstitution

Injection Technique & Reconstitution

  1. Remove flip-top cap from the vial
  2. Swab rubber stopper with alcohol swab
  3. Draw 1 mL sterile water or bacteriostatic water
  4. Inject slowly down the vial wall
  5. Gently swirl until dissolved
  6. Label with reconstitution date; refrigerate at 2-8C
Calculate your Thymosin Alpha-1 dose

Use our free peptide dosage calculator to get the exact syringe units for your vial size and dose.

Peptide dosage calculator →

Mechanism of Action

Thymosin Alpha-1 modulates innate and adaptive immunity through multiple mechanisms. It stimulates dendritic cell maturation and antigen presentation, enhances T helper cell (Th1) responses, and promotes cytotoxic T lymphocyte (CTL) activity against virally infected or cancerous cells. It activates natural killer (NK) cells and increases production of interferon-gamma, IL-2, and IL-12. TA1 binds Toll-like receptor 9 (TLR9) to stimulate innate immune responses. In chronic viral infections (hepatitis B, C, HIV), TA1 reverses T-cell exhaustion and restores immunocompetence. It also increases dendritic cell MHC II expression for improved antigen presentation.

Key Research Papers

Thymosin alpha 1 in the treatment of hepatitis B and C: a meta-analysis 2011

Meta-analysis confirming significant improvement in sustained virological response in chronic hepatitis B and C patients treated with Thymosin Alpha-1.

View on PubMed →
Thymosin alpha-1 activates dendritic cells for anti-tumor immunity 2015

Demonstrated Thymosin Alpha-1 activation of dendritic cells via TLR9 signaling, enhancing anti-tumor cytotoxic T lymphocyte responses.

View on PubMed →

Stacks Well With

Epithalon

Longevity and immune optimization stack - Epithalon addresses cellular aging while Thymosin Alpha-1 maintains immune competence, both critical for healthy aging.

LL-37

Comprehensive immune support - Thymosin Alpha-1 modulates adaptive immunity while LL-37 provides innate antimicrobial protection.

BPC-157

Recovery stack during illness - BPC-157 supports tissue repair while Thymosin Alpha-1 enhances immune clearance of infection.

Frequently Asked Questions